<DOC>
	<DOCNO>NCT01872260</DOCNO>
	<brief_summary>The purpose trial inform future clinical development two investigational agent ER+ breast cancer , LEE011 ( CDK4/6 inhibitor ) BYL719 ( PI3K-alpha inhibitor ) . This multi-center , open-label Phase Ib study . The Phase Ib dose escalation estimate MTD and/or RP2D three regimen : two double combination , LEE011 letrozole BYL719 letrozole , follow triple combination LEE011 + BYL719 letrozole ( Arms 3 4 ) . The Phase Ib dose escalation part follow Phase Ib dose expansion characterize safety , tolerability , PK preliminary clinical anti-tumor activity combination . Optional crossover patient progress dose escalation dose expansion doublet treatment Arms 1 2 treated triplet combination ( Arm 3 ) determination RP2D Arm 3 ; longer permit protocol amendment 6 . Approximately 225 adult woman ER+/HER2- locally advance metastatic breast cancer enrol .</brief_summary>
	<brief_title>Study LEE011 , BYL719 Letrozole Advanced ER+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal , Estrogenreceptor positive and/or Progesteronereceptor positive breast cancer Phase Ib dose escalation : Any number prior line endocrine therapy allow exception cytotoxic therapy limit one prior line administer advance ( metastatic locally advanced ) set . Phase Ib dose expansion Arms 1 , 2 3 No prior systemic treatment advance ( metastatic locally advanced ) set exception treatment letrozole maximum one month prior start study treatment . Patients receive ( neo ) adjuvant therapy breast cancer eligible . Prior therapy letrozole anastrozole ( neo ) adjuvant set permit diseasefree interval great 12 month completion treatment . HER2overexpression patient 's tumor tissue Patients active CNS brain metastasis Major surgery within 2 week Acute chronic pancreatitis Bilateral diffuse lymphangitic carcinomatosis Another malignancy within 3 year Receiving hormone replacement therapy discontinue Impaired cardiac function Patients clinically manifest diabetes mellitus ( treat and/or clinical sign fast glucose â‰¥ 126 mg/dL / 7.0 mmol/L hemoglobin A1c &gt; 6.5 % ) , history gestational diabetes mellitus document steroidinduced diabetes mellitus . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hormone-receptor positive</keyword>
</DOC>